Moleculin Biotech Announces Its Miracle Trial Reports 37% Blinded Complete Remission In Venetoclax-failed R/R AML Patients
https://www.sec.gov/ix?doc=/Archives/edgar/data/1659617/000143774926025167/mbrx20260729_8k.htm
A company testing a new leukemia treatment found that it helped 37% of patients whose previous medicine stopped working. When you see this kind of news, it's worth noticing whether the results are better than what doctors usually expect, but remember that early test results don't always mean the medicine will work the same way for everyone.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.